Show simple item record

dc.contributor.authorMorgan, Richard*
dc.contributor.authorEl-Tanani, Mohamed*
dc.contributor.authorHunter, K.D.*
dc.contributor.authorHarrington, K.J.*
dc.contributor.authorPandha, H.S.*
dc.date.accessioned2017-03-16T12:03:39Z
dc.date.available2017-03-16T12:03:39Z
dc.date.issued2017-03-07
dc.identifier.citationMorgan R, El-Tanani M, Hunter KD et al (2017) Targeting HOX/PBX dimers in cancer. Oncotarget. 8(19): 32322-32331.en_US
dc.identifier.urihttp://hdl.handle.net/10454/11620
dc.descriptionYesen_US
dc.description.abstractThe HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also dysregulated in a wide range of solid and haematological malignancies and have a predominantly pro-oncogenic function. A key mode of transcriptional regulation by HOX and PBX proteins is through their interaction as a heterodimer or larger complex that enhances their binding affinity and specificity for DNA, and there is growing evidence that this interaction is a potential therapeutic target in malignancies that include prostate, breast, renal, ovarian and lung cancer, melanoma, myeloma, and acute myeloid leukaemia. This review summarizes the roles of HOX and PBX genes in cancer and assesses the therapeutic potential of HOX/PBX dimer inhibition, including the availability of biomarkers for its application in precision medicine.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttp://dx.doi.org/10.18632/oncotarget.15971en_US
dc.rights© 2017 Morgan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.subjectHOX; PBX; HXR9; Targeted therapy; Biomarkeren_US
dc.titleTargeting HOX/PBX dimers in canceren_US
dc.status.refereedYesen_US
dc.date.Accepted2017-02-23
dc.date.application2017-03-07
dc.typeArticleen_US
dc.type.versionPublished versionen_US


Item file(s)

Thumbnail
Name:
Morgan_Oncotarget.pdf
Size:
970.7Kb
Format:
PDF
Description:
To keep suppressed
Thumbnail
Name:
Morgan_et_al_Oncotarget.pdf
Size:
1.039Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record